Single genetic mutations can account for melanocytic naevi
R.W. Blewitt,
R.W. Blewitt
Department of Pathology, Royal Lancaster Infirmary, Lancaster LA1 4RP, U.K.
Search for more papers by this authorR.W. Blewitt,
R.W. Blewitt
Department of Pathology, Royal Lancaster Infirmary, Lancaster LA1 4RP, U.K.
Search for more papers by this authorR.W. Blewitt.
E-mail: [email protected]
Conflicts of interest: None declared.
Summary
Background The nature of melanocytic naevi is unknown notwithstanding their considerable significance for clinician and pathologist and despite the wealth of existing knowledge about melanocyte biology.
Objectives To investigate how far a simple mutational model can explain the clinical and pathological features of melanocytic naevi, in particular their pattern of onset and frequency.
Methods I have constructed a model of the development of the adult melanocyte population from a single stem cell. The total cutaneous melanocyte population in a human adult is already known, as well as the range of spontaneous mutation rates at a given gene site. For each cycle of mitosis during the post stem-cell expansion of the melanocyte population, I calculate the accumulated number of cells likely to be mutated at a particular (although unknown) gene site. The results are interpreted in the light of a hypothesis that each of these mutant melanocytes will go on to form a melanocytic naevus. Comparisons are made with neurofibromas, occurring in type 1 neurofibromatosis and as sporadic lesions.
Results A single genetic mutation in melanocyte precursors is found to be sufficient to explain the clinical and pathological features of melanocytic naevi.
Conclusions I propose that melanocytic naevi are a consequence of single spontaneous genetic mutations which inevitably occur during the development of the adult population of cutaneous melanocytes.
References
- 1 Mackie RM, English J, Aitchison TC et al. The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population. Br J Dermatol 1985; 113: 167–74.
- 2 Mehregan AH, Hashimoto K, Mehregan DA, Mehregan DR. Malformation and neoplasia. In: Pinkus's Guide to Dermatopathology, 6th edn. Norwalk, CT: Appleton & Lange, 1995; 462–7.
- 3 Happle R. What is a nevus? A proposed definition of a common medical term. Dermatol 1995; 191: 1–5.
- 4 Walton RG, Jacobs AH, Cox AJ. Pigmented lesions in newborn infants. Br J Dermatol 1976; 95: 389–96.
- 5 Lutd HZ, Stobbe GD. The natural history of the pigmented nevus: factors of age and anatomic location. Am J Pathol 1949; 25: 1117–45.
- 6 Shelley WB. Photographic evidence of the spontaneous involution and disappearance of pigmented nevi; case report. Arch Dermatol 1960; 81: 208–9.
- 7 Harper JI. Genetics and genodermatoses. In: Textbook of Dermatology ( RH Champion, JL Burton, DA Burns, SM Breathnach, eds), 6th edn, Vol. 1. Oxford: Blackwell Science, 1998; 357–436.
- 8 Serra E, Puig S, Otero D et al. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am J Hum Genet 1997; 61: 512–19.
- 9 Osborn MJ, Upadhyaya M. Evaluation of the protein truncation test and mutation detection in the NF1 gene: mutational analysis of 15 known and 40 unknown mutations. Hum Genet 1999; 105: 327–32.DOI: 10.1007/s004390051109
- 10
Weiss B,
Bollag G,
Shannon K.
Hyperactive ras as a therapeutic target in neurofibromatosis type 1.
Am J Med Gen
1999; 89: 14–22.
10.1002/(SICI)1096-8628(19990326)89:1<14::AID-AJMG5>3.0.CO;2-4 CAS PubMed Web of Science® Google Scholar
- 11 Sawada S, Florell S, Purandare SM et al. Identification of NF1 mutations in both alleles of a dermal neurofibroma. Nat Genet 1996; 14: 110–12.DOI: 10.1038/ng0996-110
- 12 Rosdahl I, Rorsman H. An estimate of the melanocyte mass in humans. J Invest Dermatol 1983; 81: 278–81.DOI: 10.1111/1523-1747.ep12518318
- 13 Simpson AJG. The natural somatic mutation frequency and human carcinogenesis. Adv Cancer Res 1997; 71: 209–40.
- 14 Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991; 51: 3075–9.
- 15 Boyer JC, Farber RA. Mutation rate of a microsatellite sequence in normal human fibroblasts. Cancer Res 1998; 58: 3946–9.
- 16 Morris JA. Spontaneous mutation rate in retinoblastoma. J Clin Pathol 1990; 43: 496–8.
- 17 Orr-Weaver TL, Weinberg RA. A checkpoint on the way to cancer. Nature 1998; 392: 223–4.DOI: 10.1038/32520
- 18 Nordlund JL. Introduction to the biology of the pigment system. In: Dermatology ( SL Moschella, HL Hurley, eds), 3rd edn. Philadelphia: W.B.Saunders, 1992; 1421–41.
- 19 Jakubovic HR, Ackerman AB. Structure and function of skin: development, morphology and physiology. In: Dermatology ( SL Moschella, HL Hurley, eds), 3rd edn. Philadelphia: W.B.Saunders, 1992; 3–87.
- 20 Joint Formulary Committee. Prescribing for children. In: British National Formulary , Vol 42. Oxon: Pharmaceutical Press, 2001; 11.
- 21 Sagebiel RW, Odland GF. Ultrastructural identification of melanocytes in early human embryos. In: Pigmentation: its Genesis and Biologic Control ( V Riley, ed.). New York: Appleton-Century-Crofts, 1972; 43–50.
- 22 Nishimura EK, Jordan SA, Oshima H et al. Dominant role of the niche in melanocyte stem-cell fate determination. Nature 2002; 416: 854–60.DOI: 10.1038/416854a
- 23 Potten CS, Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 1990; 110: 1001–19.
- 24 Rampen FH, De Wit PE. Racial differences in mole proneness. Acta Derm Venereol 1989; 69: 234–6.
- 25 Green A, Siskind V, Hansen ME et al. Melanocytic nevi in school-children in Queensland. J Am Acad Dermatol 1989; 20: 1054–60.
- 26 Kelly JW, Rivers JK, MacLennan R et al. Sunlight: a major factor associated with the development of melanocytic nevi in Australian schoolchildren. J Am Acad Dermatol 1994; 30: 40–8.
- 27 Baird EA, McHenry PM, MacKie RM. Effect of maintenance chemotherapy in childhood on numbers of melanocytic naevi. BMJ 1992; 305: 799–801.
- 28 Hughes BR, Cunliffe WJ, Bailey CC. Excess benign melanocytic naevi after chemotherapy for malignancy in childhood. BMJ 1989; 299: 88–91.
- 29 Fitzpatrick TB, Szabo G, Mitchell RE. Age changes in the human melanocyte system. In: Aging. Proceedings of the Symposium Held at the University of Oregon Medical School 1964 (Advances in Biology of Skin, Vol. 6. ( W Montagna, ed.). Oxford: Pergamon, 1965; 35–56.
- 30 Gilchrest BA, Blog FB, Szabo G. Effects of aging and chronic sun exposure on melanocytes in human skin. J Invest Dermatol 1979; 73: 141–3.DOI: 10.1111/1523-1747.ep12581580
- 31 Mark GJ, Mihm MC, Liteplo MG et al. Congenital melanocytic nevi of the small and garment type. Clinical, histologic, and ultrastructural studies. Hum Pathol 1973; 4: 395–418.
- 32 Healy E, Belgaid CE, Taketa M et al. Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res 1996; 56: 589–93.
- 33 Maitra A, Gazdar AF, Moore TO, Moore AY. Loss of heterozygosity analysis of cutaneous melanoma and benign melanocytic nevi: laser capture microdissection demonstrates clonal genetic changes in acquired melanocytic nevi. Hum Pathol 2002; 33: 191–7.DOI: 10.1053/hupa.2002.31297
- 34 Papp T, Pemsel H, Zimmermann R et al. Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J Med Genet 1999; 36: 610–14.
- 35 McKee PH. Pathology of the Skin, 2nd edn. London: Mosby-Wolfe, 1996; 1648–9.
- 36 Mackie RM. Melanocytic naevi and malignant melanoma. In: Textbook of Dermatology ( RH Champion, JL Burton, DA Burns, SM Breathnach, eds) 6th edn, Vol. 2. Oxford: Blackwell Science, 1998; 1717–52.
- 37 Wagner SN, Ockenfels HM, Wagner C et al. Ras gene mutations: a rare event in nonmetastatic primary malignant melanoma. J Invest Dermatol 1995; 104: 868–71.DOI: 10.1111/1523-1747.ep12607039
- 38 Shahbazi M, Pravica V, Nasreen N et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002; 359: 397–401.DOI: 10.1016/S0140-6736(02)07600-6
- 39 Walker GJ, Hayward NK. p16INK4A and p14ARF tumour suppressors in melanoma: lessons from the mouse. Lancet 2002; 359: 7–8.DOI: 10.1016/S0140-6736(02)07271-9
- 40 Bartkova J, Lukas J, Guldberg P et al. The p16-cyclin D/Cdk4-pRB pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996; 56: 5475–83.
- 41 Lynch HT, Frichot BC, Lynch JF. Familial atypical multiple mole–melanoma syndrome. J Med Genet 1978; 15: 352–6.
- 42 Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol 2000; 42: 705–22.DOI: 10.1067/mjd.2000.104687
- 43 Swerdlow AJ, English J, MacKie RM et al. Benign melanocytic naevi as a risk factor for malignant melanoma. BMJ 1986; 292: 1555–9.
- 44 Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 2001; 12: 69–82.DOI: 10.1023/A:1008980919928
- 45 Johnson L, Mercer K, Greenbaum D et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001; 410: 1111–16.DOI: 10.1038/35074129
- 46 Reed SI. Control of the G1/S transition. In: Cancer Surveys, Vol. 29 ( MB Kastan, ed.). New York: Cold Spring Harbour Laboratory Press, 1997; 7–23.
- 47 Feldkamp MM, Angelov L, Guha A. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway. Surg Neurol 1999; 51: 211–18.DOI: 10.1016/S0090-3019(97)00356-X
- 48 Peeper DS, Upton TM, Ladha MH et al. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 1997; 386: 177–81.DOI: 10.1038/386177a0
